CABG and Bone Marrow Stem Cell Transplantation after Myocardial Infarction

Abstract

We encountered two cases of ruptured anastomotic pseudoaneurysms 47 and 77 months after surgery for atherosclerotic thoracic aortic aneurysms. Autopsy was performed in one case and emergency re-operation was performed in the other case. We gained some interesting findings in the autopsy and the re-operation. The anastomotic sites were sustained by sutures only, and there was no evidence of tissue supplementation at the anastomotic sites in macroscopic observation. Microscopic findings demonstrated endothelium healing on the internal side of the prosthesis near the anastomotic site. There was no tissue connection between the prostheses and the native aortic walls, although over four or six years had passed after the previous anastomoses. Anastomotic pseudoaneurysms may occur even in a long time after surgery. Careful operative procedures and long-term computed tomography or magnetic resonance imaging follow-up are crucial.

Cardiac Stem Cells and Mechanisms of Myocardial Regeneration

“…Thus these findings support the notion that BMCs adopt the cardiac phenotype and potentiate the growth reserve of the adult heart. Collectively, these observations point to the therapeutic import of BMCs for cardiac diseases in humans (17,39,69,158,163,239,273,372,373,415,421,448,449,452,528).…”

“…In spite of these uncertainties, clinical trials have been completed and some are ongoing (39,69,158,163,186,273,372,373,415,421,448,449,452,528). The safety of this approach has been documented, and double-blind clinical studies are in progress.…”

Hyperglycemia Accelerated Endothelial Progenitor Cell Senescence via the Activation of p38 Mitogen-Activated Protein Kinase

“…There are no specific studies in the literature on therapeutic revascularization with cell therapy for diabetic patients, although many studies have demonstrated that diabetic patients displayed poorer responses to cell therapy than non-diabetic patients. [20][21][22][23][24][25][26][27][28][29][30] Indeed, Tamarat et al demonstrated a reduced angiogenic potential of EPCs in diabetic animals. Administration of diabetic progenitors into the ischemic hindlimbs of non-diabetic mice improved angiogenic response to a lesser extent.…”

Bone Marrow Derived Pluripotent Stem Cells in Ischemic Heart Disease: Bridging the Gap Between Basic Research and Clinical Applications

“…While there were no significant differences between the groups, patients treated with selected CD34+/CXCR4+ cells showed trends of improvement in LV function when compared to controls. Other studies utilizing primitive populations of BM-SPCs such as CD133+ cells have reported improvement of LV function and perfusion (Bartunek et al, 2005;Stamm et al, 2004).…”